Cargando…

Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors

Although mutations in the phosphoinositide 3‐kinase catalytic subunit (PIK3CA) are common in breast cancer, PI3K inhibitors alone have shown modest efficacy. We sought to identify additional pathways altered in PIK3CA‐mutant tumors that might be targeted in combination with PI3K inhibitors. We gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merino, Vanessa F., Cho, Soonweng, Liang, Xiaohui, Park, Sunju, Jin, Kideok, Chen, Qian, Pan, Duojia, Zahnow, Cynthia A., Rein, Alan R., Sukumar, Saraswati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527464/ https://www.ncbi.nlm.nih.gov/pubmed/28296140 http://dx.doi.org/10.1002/1878-0261.12053

Ejemplares similares

BRCA1: linking HOX to breast cancer suppression
por: Jin, Kideok, et al.
Publicado: (2010)

A pivotal role for HOXB7 protein in endocrine resistant breast cancer
por: Jin, Kideok, et al.
Publicado: (2015)

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
por: Wang, Dong, et al.
Publicado: (2016)

IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
por: Zorea, Jonatan, et al.
Publicado: (2018)

Somatic mutation and gain of copy number of PIK3CA in human breast cancer
por: Wu, Guojun, et al.
Publicado: (2005)

PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor
por: Liu, Fengchao, et al.
Publicado: (2020)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells
por: Kim, Hyun-Jung, et al.
Publicado: (2016)

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
por: Hua, Yaping, et al.
Publicado: (2022)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

Targeting glutamine metabolism in PIK3CA mutant colorectal cancers
por: Feng, Xiujing, et al.
Publicado: (2016)

Surgical management for isolated macrodactyly in an adult PIK3CA mutant
por: Jacobs, C.J., et al.
Publicado: (2020)

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
por: Cataldo, Maria Letizia, et al.
Publicado: (2023)

Activation of diverse signaling pathways by oncogenic PIK3CA mutations
por: Wu, Xinyan, et al.
Publicado: (2014)

HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24
por: Teo, Wei Wen, et al.
Publicado: (2016)

STAT3 and its targeting inhibitors in osteosarcoma
por: Liu, Yun, et al.
Publicado: (2020)

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
por: Huw, L-Y, et al.
Publicado: (2013)

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer
por: Park, Yoon Sun, et al.
Publicado: (2023)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
por: Wang, Shu, et al.
Publicado: (2020)

Icaritin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling
por: Wu, Jinfeng, et al.
Publicado: (2016)

Identification of effective natural PIK3CA H1047R inhibitors by computational study
por: Liu, Naimeng, et al.
Publicado: (2021)

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
por: Sinnberg, Tobias, et al.
Publicado: (2016)

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2016)

LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis
por: Li, Huili, et al.
Publicado: (2011)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

Mutant PIK3CA Induces EMT in a Cell Type Specific Manner
por: Bhagirath, Divya, et al.
Publicado: (2016)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma
por: Hong, Christopher S., et al.
Publicado: (2022)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
por: Yoshida, Takahiro, et al.
Publicado: (2016)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

Study of Imidazolium Salt Derivatives as PIK3CA Inhibitors Using a Comprehensive in Silico Method
por: Wang, Ming-yang, et al.
Publicado: (2018)

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2018)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Oncogenic β-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids
por: Riemer, Pamela, et al.
Publicado: (2017)

Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
por: McCann, Georgia A., et al.
Publicado: (2014)

The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression
por: Poria, Dipak K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r20l96o58q46a97e1u3jgv5k6p